Alpha 2.0
Login Register
» Articles » PMID: 20408872

Postimatinib Therapy Emergence of a New JAK2V617F Clone and Subsequent Development of Overt Polycythemia Vera in a Patient with Chronic Myelogenous Leukaemia

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2010 Apr 23
PMID 20408872
Citations 9
Authors
Ayalew Tefferi
Ralph Levitt
Terra L Lasho
Ryan A Knudson
Rhett P Ketterling
Affiliations
Soon will be listed here.
Citing Articles

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.

Zanelli M, Bisagni A, Sanguedolce F, Broggi G, Fragliasso V, Zizzo M Front Oncol. 2024; 13:1329298.

PMID: 38282677 PMC: 10811046. DOI: 10.3389/fonc.2023.1329298.

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

Tosoni L, Fabbro D, Pizzano U, Mullai R, Morelli G, Franzoni A Ann Hematol. 2023; 102(5):1279-1280.

PMID: 36947213 DOI: 10.1007/s00277-023-05187-5.

Emergence of Chronic Myeloid Leukemia in a -V617F Polycythemia Vera.

Lorenzo M, Grille S, Stevenazzi M J Hematol. 2020; 9(1-2):23-29.

PMID: 32362982 PMC: 7188376. DOI: 10.14740/jh591.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Bader G, Dreiling B J Investig Med High Impact Case Rep. 2019; 7:2324709619832322.

PMID: 30803277 PMC: 6393948. DOI: 10.1177/2324709619832322.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Soderquist C, Ewalt M, Czuchlewski D, Geyer J, Rogers H, Hsi E Mod Pathol. 2018; 31(5):690-704.

PMID: 29327708 PMC: 6008160. DOI: 10.1038/modpathol.2017.182.